What Lotan Plus Treats: Main Uses and Benefits

Lotan Plus is commonly used for the management of symptoms linked to chronic high blood pressure (hypertension) when symptoms related to systemic imbalance or heightened physiological activity is used when combined symptomatic support may be appropriate. This therapy is applied in addressing symptom clusters that create noticeable physiological strain. It is used to help with symptom clusters that create noticeable functional strain in patients with certain associated risk factors, and it may assist with maintaining functional stability during symptomatic phases.

The medication is relevant for easing symptoms that interfere with daily functioning and is considered appropriate for conditions marked by increased physiological stress. The primary uses generally center on is applied in addressing symptoms linked to organ-specific functional stress and offers supportive therapeutic benefit for symptoms related to heightened physiological activity. This combination is often applied in scenarios requiring additional symptomatic assistance.

“It provides support that helps ease the overall symptom burden associated with systemic imbalance.”

Support for consistent blood pressure contributes to easing the overall symptom load linked to heightened physiological activity.

---

Quick Fact: Relief for Systemic Imbalance Lotan Plus supports patients during episodes of heightened discomfort by helping to manage symptoms related to systemic imbalance, which may help improve day-to-day comfort during symptomatic periods.

Regulatory References

1. DailyMed NLM Overview of Losartan/Hydrochlorothiazide

Eligibility Map: Who can and cannot use Lotan Plus

Official regulatory documents define the population eligible to use Lotan Plus (Losartan Potassium and Hydrochlorothiazide) and strictly prohibit its use in several key groups.

Classification	Population Group Restriction	Regulatory Basis
Contraindicated	Pregnancy: Use during the second and third trimesters is strictly prohibited, and the drug must be discontinued as soon as pregnancy is detected.	Fetal Toxicity Black Box Warning
Contraindicated	Patients with Anuria (inability to form urine).	HCTZ Component
Contraindicated	Patients with Severe Renal Impairment (creatinine clearance leq 30 mL/min).	Organ Function
Contraindicated	Patients with Severe Hepatic Impairment, cholestasis, or biliary obstructive disorders.	Organ Function
Contraindicated	Patients with Hypersensitivity to losartan, hydrochlorothiazide, or any sulfonamide-derived drugs.	Allergy/Hypersensitivity
Contraindicated	Diabetic patients or patients with renal impairment (GFR < 60 mL/min/1.73 m^2) concurrently taking aliskiren.	Drug Interaction Rule
Not Recommended	Pediatric patients and adolescents (under 18 years of age).	Safety/Efficacy Not Established
Not Recommended	Nursing Mothers (Breastfeeding).	Potential Infant Risk
Conditional Use	Patients with Volume or Salt Depletion must have this condition corrected prior to initiating therapy.	Pre-existing Condition Rule

Age-Related Eligibility: The fixed-dose combination product is approved for use in Adults. It is not recommended for the pediatric population under 18 years due to a lack of established safety and effectiveness data. Dosage adjustment is generally not necessary for older adults.

Official Eligibility Statements: The eligibility status is officially classified by regulators as Contraindicated (absolute prohibition), Not Recommended (use should be avoided), and Conditional Use (requires pre-correction of a condition).

The eligibility profile strictly limits use based on physiological status, organ function, and specific comorbidities, ensuring adherence to mandated population exclusion criteria.

Interactions with other Medicines and Products

This section outlines documented interactions for Lotan Plus (Losartan/Hydrochlorothiazide) based strictly on authoritative government regulatory information. This information should not be interpreted as medical advice.

---

Documented Interaction Categories

Category	Relevant Interacting Agents/Substances
Exposure Modifiers	Fluconazole ( CYP2C9 inhibitor); Phenobarbital (enzyme inducer)
Pharmacodynamic Additive Effects	Other Antihypertensive agents; Potassium-sparing diuretics; Potassium supplements
Absorption Affecting Agents	Cholestyramine and Colestipol resins

---

Official Regulatory Constraints

Regulatory documents identify specific constraints concerning co-administration:

• Contraindicated Combination: The co-administration of Aliskiren is contraindicated in patients with diabetes mellitus due to increased risk of renal impairment, hyperkalemia, and hypotension.
• Potassium Levels: Concomitant use with potassium-sparing agents or potassium supplements increases the risk of hyperkalemia.
• Other Antihypertensives: Co-administration with other blood pressure medicines may lead to additive hypotensive effects.
• Non-Drug Substances: Consumption of alcohol may increase the effects of the tablets. Grapefruit juice may affect losartan exposure, and its use is generally advised against.
• Special Populations: The risk of adverse renal effects when combining with NSAIDs is of particular concern for elderly or volume-depleted patients.

This information is presented for educational purposes only and reflects the known interaction profile from official regulatory labeling.

How Lotan Plus Works

Lotan Plus exerts its effects through two distinct mechanistic domains: Angiotensin II Receptor Antagonism (Losartan) and Diuresis (Hydrochlorothiazide).

️ Angiotensin II AT1 Receptor Blockade

This domain involves the active mechanism of Losartan, a selective and competitive Angiotensin II Receptor Blocker (ARB). It acts within domains involving receptor-mediated signaling by inhibiting the binding of the vasoconstrictor Angiotensin II to the AT1 receptor, primarily in vascular smooth muscle and the adrenal gland. The resulting physiological effect is a reduction in Angiotensin II-mediated vasoconstriction, which results in vasodilation and a subsequent reduction in peripheral resistance.

Modulation of Renal Fluid and Electrolyte Homeostasis

This domain involves the active mechanism of Hydrochlorothiazide, a thiazide-type diuretic. The drug engages mechanisms that influence ion transport by modulating the movement of sodium and chloride ions in the distal convoluted tubule of the nephron. This action modifies early molecular steps that shape systemic physiological outcomes by promoting natriuresis and diuresis, which attenuates the impact of excessive mediator activity (like aldosterone) and decreases overall plasma volume.

Lotan Plus is administered orally as a film-coated tablet and is taken once daily. The tablet should be swallowed whole with fluid, and administration is permitted with or without food.

The use of this fixed-dose combination (FDC) is generally reserved for individuals whose blood pressure remains insufficiently controlled on monotherapy with either Losartan or Hydrochlorothiazide alone, defining its position as a later-stage regimen rather than initial therapy.

The standard maintenance dose is Losartan 50 mg combined with Hydrochlorothiazide 12.5 mg once daily. If blood pressure control remains inadequate, the dosage may be adjusted upward after approximately three weeks of therapy. The maximum approved dose is Losartan 100 mg combined with Hydrochlorothiazide 25 mg once daily. This regimen achieves its full antihypertensive effect within three to four weeks of initiation.

Administration Rules for Specific Populations

Constraints regarding specific patient groups apply. Lotan Plus is not recommended for patients with severe renal impairment (creatinine clearance <30 ml/min) and is contraindicated in severe hepatic impairment. While dosage adjustment is not usually necessary for older adults or those with moderate renal impairment, the FDC is not recommended for use in children and adolescents under 18 years of age due to lack of established data.

If a scheduled dose is missed, the protocol involves skipping the missed dose entirely and resuming the treatment with the next planned dose; a double dose should never be taken to compensate.

Lotan Plus: Recent Clinical Evidence

---

Summary of Pharmacological Investigation and Observed Effect

The drug's pharmacological investigation

Studies have explored the underlying pharmacology, suggesting it involves blocking the reuptake of both norepinephrine and dopamine. Research has evaluated whether this observation is associated with mood changes in individuals with Major Depressive Disorder (MDD).

Trial findings in Major Depressive Disorder (MDD)

Research has examined the observed effect of the sustained-release formulation. Findings suggest changes in measured depressive symptom scores were noted over a 12-week period.

One study compared outcomes to other antidepressants; the findings suggested a lower incidence of sexual side effects compared to the comparator treatment.

The primary studies evaluated the drug's effect across various MDD sub-populations, including individuals experiencing significant anxiety.

---

Key Clinical Trials

Core Efficacy Trial (12-Week Phase 3)

• Study Design: A Phase 3, randomized, double-blind, placebo-controlled trial of 450 adult participants diagnosed with MDD.
• Duration: 12 weeks.
• Primary Outcome: Change from baseline in the Hamilton Depression Rating Scale (HDRS-17) score, a tool used to evaluate scores on the scale.
• Secondary Outcomes: Sustained remission rates at 12 weeks, an outcome that was defined as achieving a specified low HDRS-17 score for a defined period. Response rates (defined as 50% reduction in HDRS-17 score).

Off-Label Exploratory Studies

An observational study examined the drug's effect when used in combination for individuals with Fibromyalgia Syndrome (FMS). The study reported a potential association with changes in reported pain scores. The study protocol specified that individuals with a history of seizures were excluded from participation in the trials.

Key Studies & References

1. Guideline for the treatment of Major Depressive Disorder (MDD) in adults (e.g., APA/NICE).

Common questions about Lotan Plus (FAQ)

Q: How quickly should I expect Lotan Plus to start working?

According to official product information, the diuretic component (Hydrochlorothiazide) begins its action within two hours, with the strongest effect occurring around four hours after taking the tablet. However, the full, lasting effect of Lotan Plus on lowering blood pressure is typically achieved only after three to four weeks of continuous use.

Q: Are there common long-term effects associated with Lotan Plus use?

Studies and official information indicate that long-term use of the Hydrochlorothiazide component is associated with an increased risk of Non-Melanoma Skin Cancer (NMSC). Additionally, official documentation mentions risks concerning Metabolic and Electrolyte Imbalance and potential changes in kidney function.

Q: Does Lotan Plus interact with common pain relievers like ibuprofen?

Official regulatory documents state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen may slightly reduce the blood pressure-lowering effect of Lotan Plus. Regulatory warnings indicate that combining the two may increase the risk of adverse renal effects, especially for older or volume-depleted patients.

Q: Are there any specific dietary considerations while taking Lotan Plus (e.g., potassium intake)?

Official guidance advises against consuming Grapefruit juice as it may impact how the Losartan component works in the body. Concomitant use with potassium-sparing diuretics or potassium supplements increases the risk of hyperkalemia (high potassium levels). Official guidance warns that use of potassium-containing salt substitutes may increase the risk of hyperkalemia.

Q: Can Lotan Plus cause a cough, and if so, how is it different from other blood pressure medicines?

Official regulatory documents list cough as a Common Adverse Reaction. This is based on clinical trial data and is categorized under documented respiratory effects.

Q: Is it common to feel dizzy or lightheaded when first starting Lotan Plus?

Dizziness is listed as a Common Adverse Reaction, occurring in 1% to 10% of patients. Official product information notes that dizziness or lightheadedness can occur, especially when moving quickly from a lying or sitting position, and this is more frequently observed when treatment is first initiated or when the dosage is adjusted.

Q: Can Lotan Plus cause changes in my blood sugar levels?

Regulatory information notes that Lotan Plus has constraints on its use in patients with diabetes. This is because the Hydrochlorothiazide component is associated with risks of Metabolism and Nutrition Disorders and may potentially cause high blood sugar (hyperglycemia).

Q: What kind of monitoring is recommended while taking Lotan Plus?

Official regulatory guidance identifies the need for periodic monitoring of serum potassium and renal function (kidney function) while taking this medication. Patients are also monitored for signs of general fluid or electrolyte imbalance, such as low sodium or low potassium.

Q: Can Lotan Plus affect my ability to drive or operate machinery?

Official product information notes that because side effects like dizziness or drowsiness may occasionally occur, especially when starting treatment or increasing the dose, the potential for these effects suggests that the ability to drive or operate machinery may be affected.

Q: Can Lotan Plus cause swelling in the ankles or feet?

Swelling (edema) is listed as a Common Adverse Event in the safety profile. Official patient labeling includes swelling of the feet, ankles, or hands (peripheral edema) as a documented event that may be associated with fluid imbalance.

Q: What happens if I accidentally take two doses of Lotan Plus close together?

Regulatory guidance on overdose states that taking too much of this medication is most likely to cause hypotension (very low blood pressure) and possibly tachycardia (rapid heart rate). If symptoms of overdose occur, official regulatory guidance indicates the need for immediate medical assistance.

Q: Is Lotan Plus safe for people with pre-existing liver conditions?

Lotan Plus is contraindicated (absolutely prohibited) in patients with severe liver impairment. For patients with mild to moderate liver impairment, official documents describe constraints on use. The product is not recommended in cases of severe liver impairment.

Q: Does taking Lotan Plus impact fertility?

Studies on animals (mice and rats) using Losartan and Hydrochlorothiazide showed no adverse effects on fertility in either sex. Official documents indicate there is no definitive data available regarding the specific effect on human fertility.

Q: What are the general expectations for blood pressure control with Lotan Plus?

Lotan Plus is indicated to treat hypertension (high blood pressure) to effectively lower blood pressure levels. Official regulatory studies have shown that lowering blood pressure reduces the risk of serious cardiovascular events, primarily strokes and myocardial infarction (heart attack).

Q: Can Lotan Plus affect sleep patterns or cause insomnia?

Yes, regulatory documents list Insomnia (trouble sleeping) as a Common Adverse Reaction, meaning it has an incidence rate of 1% to 10% and is classified under documented Psychiatric Disorders.

Q: Is there a known 'ceiling' effect where increasing the dose of Lotan Plus doesn't help more?

The maximum approved dose is specified in the regulatory labeling as Losartan 100 mg combined with Hydrochlorothiazide 25 mg once daily. The approved clinical trial data and regulatory labeling only evaluate and support the maximum specified dose. Doses higher than this are not approved for use.

Q: Can men and women expect different effects from taking Lotan Plus?

Studies show that while blood concentrations of Losartan may be higher in female patients compared to male patients, the concentrations of the active metabolite (the substance primarily responsible for the therapeutic effect) were reported to be similar in males and females.

Q: Is there a link between Lotan Plus and hair loss?

Official regulatory safety information lists hair loss (Alopecia) as an infrequently reported side effect.

Q: What is the risk of an allergic reaction to Lotan Plus?

The medication is contraindicated (should not be used) in anyone with a known hypersensitivity or allergy to any component, including sulfonamide-derived drugs. The most serious type of allergic reaction, known as Angioedema, may involve swelling of the face, lips, throat, or tongue, and is a condition that necessitates immediate medical assessment.

The storage and disposal requirements for Lotan Plus (losartan potassium and hydrochlorothiazide) are set by official regulatory labeling.

Storage Requirements

Condition	Official Requirement
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Do not freeze or refrigerate.
Protection	Keep in the original container, protected from moisture and light.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Disposal must follow local regulations. If a drug take-back program is unavailable, unused or expired tablets should be prepared for safe disposal in the household trash. This involves mixing the medicine with an undesirable substance (e.g., used coffee grounds) and sealing the mixture in a container. It is prohibited to flush the tablets down the toilet or sink, unless the drug’s official labeling specifies otherwise.